References
- Chamie K, Litwin M, Bassett J, Daskivich T, Lai J, Hanley J, et al. Recurrence of high-risk bladder cancer: A population-based analysis. Cancer 2013;119:3219–27.
- Shida K, Shimasaki J, Takahashi H, Kurihara H, Sato J. Therapy and prognosis of bladder tumors – result of injection of mitomycin C into the bladder. Gan No Rinsho 1970;16(7):737–44.
- Logan C, Brown M, Hayne D. Intravesical therapies for bladder cancer – indications and limitations. BJU Int 2012;110(Suppl4):12–21.
- Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review. Eur Urol 2011;60:81–93.
- Babjuk M, Burger M, Zigeuner R, Comperat E, Kaasinen E, Palou J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2014. Available at http://www.uroweb.org/guidelines/online-guidelines/
- Sousa A, Inman B, Piñeiro I, Monserrat V, Pérez A, Aparici V, et al. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. chemotherapy HIVECfor treating and - NMIBC. Int J Hyperthermia 2014;30:166–70.
- Eisenhauera E, Therasseb P, Bogaertsc J, Schwartzd L, Sargente D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
- Inman BA, Etienne W, Rubin R, Owusu RA, Oliveira TR, Rodriques DB, et al. The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment. Int J Hyperthermia 2013;29:206–10.
- Dalton JT, Wientjes MG, Badalament RA, et al. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1991;51:5144–52.
- Paroni R, Salonia A, Lev A, Da Pozzo LF, Cighetti G, Montorsi F, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52:273–8.
- Milla P, Fiorito C, Soria F, Arpicco S, Cattel L, Gontero P. Intravesical thermo-chemotherapy based on conductive heat: A first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients. Cancer Chemother Pharmacol 2014;73:503–9.
- Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia 2014;30:171–5.
- Colombo R, Da Pozzo LF, Lev A, Salonia A, Rigatti P, Leib Z, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 1998;159:783–7.
- Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: Preliminary results of a randomised phase 2 study. Eur Urol 2012;62(5):797–802.
- Lüdecke G, Schäfer L, Nativ O, Witzsch U, Hanitzsch H, Hasner F, et al. Radiofrequence induced hyperthermia chemotherapy in high-risk NMIBC: Multiinstitutional, international outcome analysis of 271 treated patients with a follow-up time of more than 2 years. Eur Urol Suppl 2015;14:949–949a.
- Arends TJH, Nativ O, Maffezzini M, De Cobelli O, Van Der Heijden AG, Witjes JA. Results of the first randomized controlled trial comparing intravesical radiofrequency induced chemohyperthermia with mitomycin-C versus BCG for adjuvant treatment of patients with intermediate and high risk NMIBC. Eur Urol Suppl 2015;14:944
- Ekin RG, Akarken I, Cakmak O, Tarhan H, Celik O, Ilbey YO, et al. Results of intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder cancer. Asian Pac J Cancer Prev 2015;16:3241–5.
- Ekin RG, Akarken I, Zorlu F, Tarhan H, Kucuk U, Yildirim Z, et al. Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer. Can Urol Assoc J 2015;9:278–83.
- Sousa A, Piñeiro I, Aparici V, Neira P, Monserrat V, Uribarri C. Analysis of budgetary impact of nonmuscle invasive vesical cancer of moderate–high risk by means of neoadjuvant hyperthermic chemotherapy compared to the standard adjuvant treatment with BCG. Arh Esp Urol 2015;68:482–92.